Hutchmed receives China NMPA conditional approval for Orpathys to treat gastric cancer patients with MET amplification: Hong Kong, Shanghai Saturday, July 4, 2026, 11:00 Hrs [IST] ...

AstraZeneca's selective MET inhibitor Orpathys has won conditional approval in China for a new indication in MET-amplified ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...

QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDAPivotal Phase 3 Study Expected to Initiate ...

Summary: For years, the “gender bias” in autism—where males are diagnosed 3–4 times more often than females—has been a biological enigma. A breakthrough study finally provides an answer. Researchers ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it ...

Last 28 March 2025, the European Commission decided not to renew the conditional marketing authorisation for Translarna (ataluren) in Duchenne’s disease due to lack of efficacy after 11 years in the ...

The European Medicines Agency (EMA) has turned down a conditional marketing authorization application for Blarcamesine Anavex (blarcamesine, Anavex Germany GmbH), a novel oral medication intended as ...

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas ...